Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)

Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23962449

DOI
10.1016/j.lungcan.2013.07.012

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /economics /mortality; Cisplatin /administration & dosage; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine /administration & dosage /analogs & derivatives; Humans; Lung Neoplasms /drug therapy /economics /mortality; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine /administration & dosage /analogs & derivatives

AccessionNumber
22013039077

Date bibliographic record published
10/10/2013